Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
about
Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.A Sensitive Peptide Nucleic Acid Probe Assay for Detection of BRAF V600 Mutations in Melanoma.Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
P2860
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
@en
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
@nl
type
label
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
@en
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
@nl
prefLabel
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
@en
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
@nl
P2093
P2860
P356
P1476
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma
@en
P2093
P2860
P304
P356
10.1111/JCPT.12229
P577
2014-11-10T00:00:00Z